If you have been keeping tabs on the website this week, then you’ll be aware at just how much of a booming year biotech companies are having. 

Writing for The Motley Fool, Keith Speights, discusses one more biotech that’s experiencing growth, and that’s Vertex Pharmaceuticals. 

The Boston-based company, has two treatments for cystic fibrosis on the market. Orkambi, which is set to generate around $1.3 billion, and Kalydeco, which is planned to bring in $800m.

Speights explained, “Success for these two drugs has definitely made Vertex attractive to investors, but the stock’s momentum in 2017 has resulted even more from the biotech’s pipeline. In March, Vertex announced positive results from a couple of late-stage studies evaluating a combination of tezecaftor and ivacaftor in treating CF. An approval decision from the FDA, is expected by 28 February. The biotech followed up a few months later with solid results from Phase I and Phase II studies of three different triple-combination CF therapies.”

Vertex is one of 349 companies that make up the Biotechnology GICS industry group, which is part of the 781 companies in the GICS Health Care sector. With a market value of $37.2b, places the company in the top portion of its industry group, rating 60 out of the 349 companies.

Speaking of the growth witnessed, InvestorPlace, added, “Vertex’s operational scores provide mixed results with a ranking for sales growth that is well above the industry average but rankings for operating margin and earnings growth are below average. Scores for visibility of earnings are mixed, with a ranking for earnings revisions and earnings surprises that are significantly better than average, while the score for earnings momentum is much worse than average. Vertex’s metric for return on quity is materially better than its industry group average but its ranking for cash flow is below-average. Based on these fundamental scores, Vertex Pharmaceuticals places in the top quartile of the industry group.”

Earlier this month, Vertex stock increased by 3.5% compared to its rival Galapagos, which in comparison fell 2.7%.